The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity

• 成果类型: Article
• 署名作者: Friedman, Jeffrey M.
• 署名单位: Howard Hughes Medical Institute; Rockefeller University
• 刊物名称: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
• ISSN/ISSBN: 0027-14638
• DOI: 10.1073/pnas.2415550121
• 发表日期: 2024-09-16
• 关键词: glucagon-like peptide-1; gene-expression; contains; incretin

摘要

The 2024 Lasker similar to DeBakey Clinical Medical Research Award has been given to Joel Habener and Svetlana Mojsov for their discovery of a new hormone GLP-1(7-37) and to Lotte Knudsen for her role in developing sustained acting versions of this hormone as a treatment for obesity. Each of the three had a distinct set of skills that made this advance possible; Habener is an endocrinologist and molecular biologist, Mojsov is a peptide chemist, and Knudsen is a pharmaceutical scientist. Their collective efforts have done what few thought possible-the development of highly effective medicines for reducing weight. Their research has also solved a mystery that began more than a century ago.